Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies. (2nd July 2016)

• Record Type: Journal Article
• Authors: Blau, Igor-Wolfgang; Conlon, Niall; Petermann, Robert; Nikolov, Nikolai; Plesner, Torben
• Is Part Of: Expert review of clinical immunology. Volume 12:Number 7(2016)
• Page Start: 705
• Page End: 711
• Publication Date: 2016-07-02
• Subjects: Secondary immune deficiencies -- immunoglobulin replacement -- IVIG -- SCIG -- fSCIG -- hyaluronidase -- individualized therapy; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2016.1183482
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: The number of patients with secondary immune deficiencies (SID) is on the rise, mostly since the arrival on the market of novel targeted therapies that have increased the survival rates of patients with hematological malignancies. The recent changes in the SID landscape have brought with them new and diverse medical needs that treatments for SID management should strive to meet. In this special report, we study the opportunities provided by facilitated subcutaneous immunoglobulin administration (fSCIg) to treat patients for whom the conventional routes (intravenous and subcutaneous) are sub-optimal. Experts in the treatment of SID describe real-life cases from their daily practice, in which fSCIg has led to reducing the burden of treatment and increasing the treatment satisfaction.